News|Podcasts|November 19, 2026

ACT Brief: Trial Matching Nudges, Federal Pressures on Biotech, and FDA Leadership Vacancy

In today’s ACT Brief, we examine how trial matching built into standard care can replace reliance on physician memory, how federal funding cuts and FDA staff losses are pressuring biotech, and why FDA is without a commissioner nominee after the White House withdrew Heidi Overton.

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

  • In the final part of a video interview, Shaalan Beg, MD, MBA, FASCO, chief medical officer at ConcertAI, outlines how integrating trial matching with standard of care workflows can replace reliance on physician memory. He argues that uniform screening can deliver timely, consistent nudges to every eligible patient.
  • A Q3 healthcare update from investment bank Cassel Salpeter & Co. cites disrupted NIH grant processing, FDA staff losses, and tariffs as pressures on drug development and early-stage financing. The report says the FDA has lost more than 3,500 employees since January 20, 2025, including 800 from CDER and almost 400 from CBER, causing major disruptions to drug development and approvals. It also warns that tariffs will disproportionately affect small and mid-sized biotechs.
  • The White House withdrew Dr. Heidi Overton’s nomination as FDA commissioner a day before a Senate committee vote, amid skepticism from several Senate Republicans. Committee chair Sen. Bill Cassidy said Overton would have had the votes to pass out of committee and the full Senate. The move leaves FDA without a permanent leader well into next year, and the White House has not said whom it might nominate next.

That’s all for today’s ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.


Related to this article